Skip to main content

Top Left Menu

Careers
Media
Investors

What are you looking for?

Keywords

Top Right Menu

You are here

Galderma Global

Choose another location

Contact us
Search

Toggle main menu visibility

Investors

Overview
Key releases
Events & presentations
Financial reports
Share information
Corporate governance
Shareholder resources

Investors

Dermatology Category Leader

View All - Dermatology Leader

Learn More

Share Price

View All - Stock Price

Learn more

Featured Presentation

Download

Latest Financial Report

H1 2024 financial results press release

Half year financial results

H1 2024 financial results press release

Download

LATEST KEY RELEASE

Key releases are ad hoc announcements pursuant to SIX Swiss Exchange Art. 53 LR

Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis

August 13, 2024

View All News

See all

NEXT UPCOMING EVENT

24

Oct

2024

Financial results

Q3 2024 trading update

See All

See All

For any queries, please contact the Galderma Investor Relations team at investors@galderma.com

Stay up-to-date

First Name

Last Name

Email Address

By providing your email address, you are giving Galderma permission to send you the Investor Email Alert updates that you have requested. For further information on how we protect your information, please refer to our Privacy Notice

STAY CONNECTED

Follow us on Social Media for current news and patients stories

Footer Social Links

© Galderma 2024

Footer Links

Terms of use
Cookie Policy
Privacy
Sitemap

Confirm navigation

You are about to leave the Nestle Skin Health global site. Are you sure you want to leave this page?

Yes, thanks Go back